Business Context and Reporting Period
This Form 8-K, dated October 2, 2020, reports a corporate name change for Unum Therapeutics Inc. The company filed a Certificate of Amendment with the Delaware Secretary of State to change its name to Cogent Biosciences, Inc. The change became effective at 12:01 a.m. Eastern Time on October 6, 2020. Concurrently, the company adopted Second Amended and Restated Bylaws to reflect the new name.
Financial Metrics
This filing is a current report regarding corporate governance and identity changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
- Corporate Name: Changed from Unum Therapeutics Inc. to Cogent Biosciences, Inc.
- Trading Symbol: Changed from "UMRX" to "COGT" on the Nasdaq Global Select Market, effective October 6, 2020.
- CUSIP: The new CUSIP for common stock is 19240Q 102.
- Bylaws: Second Amended and Restated Bylaws were approved to reflect the name change, with no other substantive changes.
Guidance, Outlook, and Disclosures
The company issued a press release on October 5, 2020, announcing the name change. A corporate presentation was furnished as Exhibit 99.2 for use in investor meetings. The filing explicitly states that the information in the press release and presentation is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth. No specific financial guidance, risk factors, or contingencies related to operations were disclosed in this specific document.
Key Facts for Investor Verification
- Verify the new ticker symbol "COGT" and CUSIP "19240Q 102" for trading purposes starting October 6, 2020.
- Confirm the effective date of the name change (October 6, 2020) for legal and record-keeping purposes.
- Review the attached corporate presentation (Exhibit 99.2) for strategic context, noting it is not a filed document under the Exchange Act.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial performance data, as this 8-K contains no financial results.